RIBOLIFE-B (06938) submits an Investigational New Drug (IND) application for a Phase I clinical trial of the dual-target drug SR122 injection for the treatment of mixed dyslipidemia and severe hypertriglyceridemia.

RIBOLIFE-B (06938) announced that the Company has submitted a Clinical Trial Application (CTA) in the European Union for a Phase I clinical trial of its self-developed dual-target siRNA drug SR122 (a GalNAc-conjugated siRNA therapy for the treatment of dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia). This CTA submission marks a further refinement of the Company's lipid pipeline strategy and represents an important step in consolidating its leading position in the field of dyslipidemia. The Company is also continuing to advance Phase II clinical studies of its core lipid-lowering product RBD5044 (the world's second most clinically advanced ApoC3-targeting siRNA therapy) in Europe and China. SR122 simultaneously targets ApoC3 and PCSK9, two clinically validated targets that play complementary roles in lipid metabolism. By simultaneously intervening in triglyceride-rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 is expected to provide a differentiated therapeutic approach, producing a stronger synergistic lipid-lowering effect in patients with severe hypertriglyceridemia, achieving durable improvements across multiple lipid parameters and cardiometabolic risk factors, and delivering a qualitative leap in patient risk management through the inhibition of complementary mechanisms. Dyslipidemia remains a major global health challenge and a primary driver of cardiovascular disease (the world's leading cause of death). Despite currently available lipid-lowering therapies, patients with mixed dyslipidemia often still face significant residual cardiovascular risk, while patients with severe hypertriglyceridemia also have an increased risk of acute pancreatitis. This Phase I clinical trial is a randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injection of SR122 in healthy subjects. The study will be the first clinical evaluation of the dual-target drug SR122 in humans and will generate key data to support its further development.